To investigate the bioavailability of dabigatran with and without concomitant administration
of digoxin and the bioavailability of digoxin with and without concomitant administration of
dabigatran etexilate
Area under the concentration-time curve of the analyte in plasma from the time point 0 after the last dose at steady state to the last quantifiable analyte plasma concentration within the uniform dosing interval τ (AUC0-tz,ss)Time of last measurable concentration of the analyte in plasma within the dosing interval τ at steady state (tz,ss)
Time from last dosing to the maximum concentration of the analyte in plasma at steady state (tmax,ss)
Apparent clearance of the analyte in the plasma at steady state after extravascular multiple dose administration (CL/Fss)
Renal clearance of the analyte at steady state determined over the dosing interval τ (CLR,ss)
Minimum measured concentration of the analyte in plasma at steady state over a uniform dosing interval τ (Cmin,ss)
Time from last dosing to the minimum concentration of the analyte in plasma at steady state over a uniform dosing interval τ ( tmin,ss)
Pre-dose concentration of the analyte in plasma at steady state immediately before administration of the next dose (Cpre,ss)
Mean residence time of the analyte in the body at steady state after p.o. administration (MRTp.o.,ss)
Fraction of parent drug eliminated in urine at steady state over a uniform dosing interval τ (feτ,ss)
Assessment of tolerability by investigator on a four point scale (good, satisfactory, not satisfactory, bad)
Apparent volume of distribution during the terminal phase λz at steady state following an extravascular administration (Vz/Fss)
Amount of analyte that was eliminated in urine at steady state over an uniform dosing interval τ (Aeτ,ss)
Area under the effect ratio curve (AUERτ,ss) for activated prothrombin time (aPTT) and ecarin clotting time (ECT)
Prolongation at trough (ERpre,ss) for aPTT
Change from baseline in physical examination
Change from baseline in vital signs (blood pressure, pulse rate)
Change from baseline in 12-lead electrocardiogram
Change from baseline in clinical laboratory tests
Number of Participants with Serious and Non-Serious Adverse Events
Maximum effect ratio at steady state (ERmax,ss) for aPTT and ECT
Prolongation at trough (ERpre,ss) for ECT
Minimum age: 18 Years.
Maximum age: 65 Years.
Gender(s): Both.